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Liberata Sportiello1, Concetta Rafaniello1, Francesco Rossi1‡ and Annalisa Capuano1‡
1 Section of Pharmacology “L. Donatelli”, Department of Experimental Medicine, Campania Pharmacovigilance and
Pharmacoepidemiology Regional Centre, University of Campania “Luigi Vanvitelli”, Naples, Italy, 2 Department of Drug Design
and Pharmacology, University of Copenhagen, Copenhagen, Denmark
Background: Despite the risk of bleeding is a well-known adverse effect of oral
anticoagulants, there is scarce evidence on the preventability of oral anticoagulant-
induced bleedings. Therefore, we investigated the potential risk factors related to
preventable cases of oral anticoagulant-induced bleedings.
Methods: We performed a study using Individual Case Safety Reports (ICSRs) with an
oral anticoagulant as suspected drug among those reported through the spontaneous
reporting system of Campania Region from 1 July 2012 to 31 December 2017. The
P-method was used for the preventability assessment of all cases of bleeding.
Results: In total, 58 cases out of 253 (22.9%) were preventable, and the most reported
suspected drug was an indirect oral anticoagulant (warfarin). Sixty-eight critical criteria
for preventability were identified, all related to healthcare professionals’ practices. The
most detected risk factor related to healthcare professionals’ practices was the labeled
drug–drug interaction for both direct and indirect oral anticoagulants.
Conclusion: Our findings describe the most reported risk factors for preventability
of oral anticoagulant-induced bleedings. These factors may be useful for targeting
interventions to improve pharmacovigilance activities in our regional territory and to
reduce the burden of medication errors and inappropriate prescription.
Keywords: oral anticoagulant, bleeding, preventability assessment, spontaneous reporting system,
adverse effect
INTRODUCTION
Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in
patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and
pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be divided
into “indirect oral anticoagulants,” like vitamin K antagonists (VKAs; warfarin, or acenocoumarol),
which have been the cornerstone of the anticoagulation therapy for decades, and into the more
recently approved “direct oral anticoagulants” (DOACs), which are selective inhibitors of single
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coagulation factors. Belongs to DOACs the reversible direct
thrombin inhibitor (dabigatran), and the direct factor Xa
inhibitors (rivaroxaban, apixaban, and edoxaban) (Sabir et al.,
2014; Monaco et al., 2017). Since their introduction, these
more recent drugs have added some advantages to the clinical
practice, like the rapid onset of action, the more predictable
pharmacokinetics and pharmacodynamics, the potentially
reduced risk for drug-drug interactions, and the absence of
routine coagulation monitoring (Mekaj et al., 2015; Eikelboom
and Merli, 2016; Hicks et al., 2016; Monaco et al., 2017). Thanks
to these properties, DOACs represent an effective alternative
to VKAs, offering also important safety advantages in terms of
risk of bleeding (Eikelboom and Merli, 2016). Accordingly, a
large phase III study has shown a consistent reduction of the
risk of cerebral hemorrhagic events with DOACs compared to
warfarin (Ruff et al., 2014), but DOACs may be associated with
a higher risk of gastrointestinal bleedings (Holster et al., 2013;
Ruff et al., 2014).
Despite the risk of bleeding is a well-known adverse effect
of oral anticoagulants that requires constant monitoring in a
real-life context, the evidence on the preventability of oral
anticoagulant-induced bleedings is meager. This can be even
more interesting considering that among predisposing causes of
anticoagulant-induced adverse drug reactions (ADRs), there are
medication errors (Piazza et al., 2011; Sessa et al., 2018a) that
represent in general an important cause of preventable ADRs
(European Medicine Agency, 2013). Moreover, the importance of
evaluating the preventability of ADRs is nowadays suggested by
both European Medicine Agency and World Health Organization
as part of pharmacovigilance-based activities to achieve an
effective risk minimization (European Medicine Agency, 2013;
Pal et al., 2015). In light of this consideration and taking into
account that no study has been conducted in our country to
directly evaluate the preventability of bleeding cases reporting an
oral anticoagulant as a suspected drug, we decided to conduct a
pharmacovigilance study on spontaneous reporting data to fill
this gap in knowledge. Therefore, the primary aim of this study
was to assess the preventability of bleeding cases reporting an
oral anticoagulant as a suspected drug among those sent through
the Campania spontaneous reporting system from July 2012
to December 2017.
MATERIALS AND METHODS
Data Source
Individual Case Safety Reports (ICSRs) with an oral anticoagulant
as a suspected drug were selected among those reported
through the spontaneous reporting system from 1 July
2012 to 31 December 2017. ICSRs were retrieved from
the Italian National database for Pharmacovigilance (Rete
Nazionale di Farmacovigilanza, RNF). This database collects
all ICSRs reported spontaneously or deriving from active
pharmacovigilance projects or observational studies. In
Italy, every healthcare institution has his own Responsible
Person for Pharmacovigilance that provides to send to the
RNF each ICSR received from a reporter. We collected for
preventability assessment only ICSRs sent to the RNF by one
Italian Region (Campania).
Descriptive and Statistical Analyses
For descriptive purposes, information on age, gender, type of
reporter, seriousness, outcome, action taken to solve the ADRs,
causality assessment, and number of reported suspected drugs
were provided separately for all cases, for all cases of bleeding,
and for “preventable” cases of bleeding. Bleeding cases were
defined as all cases that reported at least one hemorrhagic
adverse event among those described in the ICSR. Cases
without hemorrhagic events were classified as not bleeding
cases and were analyzed separately. Moreover, ICSRs were
classified based on the suspected drug in those reporting an
indirect oral anticoagulant (warfarin or acenocoumarol), and
those reporting a DOAC (dabigatran, edoxaban, rivaroxaban,
or apixaban). All reported preferred terms (PTs) related to
bleedings were tabled according to their system organ class (SOC)
(Brown et al., 1999). For gastrointestinal bleedings, when their
location in the gastrointestinal tract was available in the ICSRs,
we classified them into “upper gastrointestinal bleedings” and
“lower gastrointestinal bleedings” for each oral anticoagulant.
We classified as belonging to the group “upper gastrointestinal
bleedings” any hemorrhagic event that occurs between the
oropharynx and the ligament of Treitz, or any event that could
be highly associated with upper gastrointestinal bleedings (e.g.,
melena or hematemesis). We classified instead into the group
“lower gastrointestinal bleedings” any hemorrhagic event that
occurs from the ligament of Treitz to the anus. Reporting odds
ratio (ROR), its’ 95% confidence interval (95%CI) and the chi-
square test were computed to evaluate if the drugs undervaluation
had a lower/higher probability of lower/upper gastrointestinal
bleeding when compared to dabigatran. Dabigatran was used
as a reference drug considering that clinical evidence has
shown a higher risk of lower gastrointestinal bleeding for
this drug compared to warfarin (Kolb et al., 2018). For each
comparison, a post hoc power calculation was performed to
assess the achieved statistical power as described by Wang
and Chow (2007). For all cases of bleedings, therapeutic
indications of oral anticoagulants were tabled. Additionally,
the three most reported PTs for each SOC not related to
bleeding were tabled. For each ICSR, the seriousness of ADRs
was codified as described in the International Council on
Harmonization E2D guidelines (European Medicines Agency,
2003), whereas the outcome was categorized into six categories
(recovered, improvement, resolution with sequelae, unchanged
clinical condition, death, and not available) according to
national law. The causality assessment evaluation was performed
using the Naranjo algorithm according to the Italian Medicine
Agency (AIFA) (Naranjo et al., 1981). Finally, we showed
our contribution to the national spontaneous reporting system
in terms of pooled ICSRs using the online public report of
ADRs (RAM system).
Preventability Assessment
The P-method was used for the preventability assessment of
all cases of bleeding. This method is an algorithm developed
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by World Health Organization to assess the preventability
of ADRs reported in the spontaneous reporting system, and
it was validated by pharmacovigilance centers during the
WHO Program for International Drug Monitoring (Benkirane
et al., 2015). Moreover, it has been validated in several
projects of Campania Region that aimed to explore the use
of P-method for the preventability assessment of adverse
reactions induced by several drug classes (e.g., non-steroidal
anti-inflammatory drugs, psychotropic drugs, contrast media,
and statins) (Sessa et al., 2016b,c, 2017, 2018b). The P-method
based on three steps of evaluation. The first step involved
the causality assessment between the drug and the ADR,
and we used the Naranjo algorithm. The second step based
on the evaluation of the mechanism underlying the ADR
in terms of dependency on dose, time, patient susceptibility,
or an unknown mechanism. Finally, the last step involved
the identification of critical criteria for preventability. The
preventability criteria are classified into three sections: healthcare
professionals’ practice, product/drug, and patient. There are 16
critical criteria related to the healthcare professionals’ practice,
two critical criteria related to the product/drug, and two critical
criteria related to the patient. The criteria related to healthcare
professionals are incorrect drug dose, administration route,
duration, storage, laboratory or clinical monitoring, expired
drug, wrong indication, inappropriate prescription for patient’s
underlying medical condition or according to the characteristics
of the patient, documented hypersensitivity, labeled drug–
drug interaction, therapeutic duplication, withdrawal syndrome,
and necessary medication not given. The criteria related
to the product/drug are poor drug quality and counterfeit
drug, and the criteria related to the patient behavior are the
non-compliance and self-medication (Benkirane et al., 2015;
Sessa et al., 2016c). According to this methodology, a case
can be classified as preventable if it is found at least one
critical criterion for preventability. In this study, three clinical
pharmacologists (one medical doctor and two pharmacists) with
multiyear experience in pharmacovigilance and preventability
assessment evaluated the preventability of oral anticoagulant-
induced bleedings through a case-by-case approach. For the
entire evaluation, when the consultation of the Summary of
Product Characteristics (SmPC) was needed, those published by
the AIFA were used. Details regarding the operative framework
for preventability of ICSRs are provided elsewhere (Sessa et al.,
2016b,c, 2017).
For all preventable cases of bleeding, the time to event
was computed as the difference in days between the onset
date of the adverse event and the start date of anticoagulant
therapy. A boxplot of time to event was generated for direct and
indirect oral anticoagulants. Finally, a cases series of preventable
ICSRs was provided.
RESULTS
In the period from July 2012 to December 2017, 25,609 ICSRs
were sent to Campania Pharmacovigilance Regional Centre, of
which 453 reported an oral anticoagulant as suspected drug
contributing to the 2.4% of national ICSRs (N = 18606). The
mean age of patients was 72.5 years [standard deviation (SD):
11.2 years], with 52.3% of cases occurred in female patients.
In most ICSRs (92.1%), one medical product was reported as
a suspected drug. ICSRs were mainly classified by the reporter
as not serious (264; 58.3%). Cases classified as serious were for
17.2% related to hospitalizations, for 11.9% registered as clinically
significant conditions, for 2.4% defined as life-threatening, and
for 1.5% related to the death of the patient. In 66.9% of
cases, several actions were taken to solve the ADRs. The main
reporter was the physician with 261 (57.6%) out of 453 ICSRs.
Causality assessment was probable for 128 (28.3%) cases and
possible for 325 (71.7%) cases. Characteristics of cases were
presented in Table 1. Because in each ICSR more than one
ADR could be reported, we observed a total of 676 ADRs for
ICSRs (1.5 suspected ADRs per ICSR). A total of 399 out of
676 ADRs were not related to bleedings. Among them, the six
most reported ADRs were abnormal coagulation profile (35/399;
8.8%), epigastric abdominal pain (28/399; 7.0%), dyspepsia
(28/399; 7.0%), increased international normalized ratio (INR)
(28/399; 7.0%), anemia (21/399; 5.3%), and fluctuating INR
(16/399; 4.0%) (Table 2).
Cases of Bleeding
A total of 253 cases (55.8%) out of 453 ICSRs reported at
least one adverse event related to bleeding. Characteristics
of cases associated with bleeding events are presented in
Table 1. Specifically, a total of 161 cases related to warfarin,
35 cases to dabigatran, 21 cases to rivaroxaban, 18 cases
to acenocoumarol, 16 cases to apixaban, and two cases
to edoxaban. The most reported therapeutic indications for
direct or indirect oral anticoagulants were atrial fibrillation
and antithrombotic prophylaxis (Supplementary Table S1).
A total of 277 suspected ADRs were related to bleedings,
of which 193 were related to indirect oral anticoagulants.
For indirect oral anticoagulant, most adverse events belong
to the SOC “respiratory, thoracic, and mediastinal disorders”
(87/193; 45.1%), followed by “gastrointestinal disorders” (56/193;
29.0%), “renal and urinary disorders” (20/193; 10.4%), “vascular
disorders” (11/193; 5.7%), “nervous system disorders” (11/193;
5.7%), “skin and subcutaneous tissue disorders” (4/193; 2.1%),
“injury, poisoning and procedural complications” (2/193; 1.0%),
“musculoskeletal and connective tissue disorders” (1/193; 0.5%),
and “eye disorders” (1/193; 0.5%). For DOAC, most adverse
events belong to the SOC “gastrointestinal disorders” (37/84;
44.0%), followed by “respiratory, thoracic, and mediastinal
disorders” (14/84; 16.7%), “renal and urinary disorders” (8/84;
9.5%), “vascular disorders” (8/84; 9.5%), “nervous system
disorders” (5/84; 6.0%), “injury, poisoning, and procedural
complications” (4/84; 4.8%), “skin and subcutaneous tissue
disorders” (3/84; 3.6%), “reproductive system and breast
disorders” (3/84; 3.6%), “musculoskeletal and connective tissue
disorders” (1/84; 1.2%), and “eye disorders” (1/84; 1.2%)
(Table 3). In the evaluation of upper and lower gastrointestinal
bleedings for different oral anticoagulants, we found that only
64 of 93 (68.8%) gastrointestinal bleedings met the criteria
for classification, of this 35 were related to warfarin, five to
Frontiers in Pharmacology | www.frontiersin.org 3 April 2019 | Volume 10 | Article 425
fphar-10-00425 April 27, 2019 Time: 16:59 # 4
Mascolo et al. Preventable Cases of Oral Anticoagulant-Induced Bleeding
TABLE 1 | Demographic characteristics and distribution for the type of reporter, drug, documentation, seriousness, outcome, causality assessment, and action taken of
cases involving oral anticoagulants recognized in Campania spontaneous reporting system from July 2012 – December 2017.
Variable Level Cases of bleeding
disorders (N = 253)
Preventable cases of
bleeding disorders
(N = 58)
Total (N = 453)
Gender Female 134 (53.0) 36 (62.1) 237 (52.3)
Male 117 (46.2) 22 (37.9) 212 (46.8)
Not available 2 (0.8) – 4 (0.9)
Age Mean (standard deviation) 72.9 (10.9) 74.4 (10.9) 72.5 (11.2)
Seriousness Serious–other clinically significant
condition
29 (11.5) 5 (8.6) 54 (11.9)
Serious–death 6 (2.4) 3 (5.2) 7 (1.5)
Serious–significant or permanent
disability
– – 1 (0.2)
Serious–hospitalization 55 (21.7) 17 (29.3) 78 (17.2)
Serious–life threatening 9 (3.6) 3 (5.2) 11 (2.4)
Not defined 9 (3.6) – 38 (8.4)
Not serious 145 (57.3) 30 (51.7) 264 (58.3)
Outcome Death 6 (2.4) 3 (5.2) 7 (1.5)
Improvement 93 (36.8) 20 (34.5) 143 (31.6)
Unchanged clinical condition 18 (7.1) 9 (15.5) 23 (5.1)
Not available 52 (20.6) 6 (10.3) 129 (28.5)
Recovered 71 (28.1) 20 (34.5) 134 (29.6)
Resolution with sequelae 13 (5.1) – 17 (3.8)
Reporter Physicians 142 (56.1) 16 (27.6) 261 (57.6)
Pharmacist 95 (37.5) 40 (69.0) 124 (27.4)
Other health care professional 8 (3.2) 1 (1.7) 27 (6.0)
Patient/Citizen or other
non-healthcare professional figure
8 (3.2) 1 (1.7) 41 (9.1)
Causality Possible 152 (60.1) 43 (74.1) 325 (71.7)
Probable 101 (39.9) 15 (25.9) 128 (28.3)
Action taken Yes 176 (69.6) 44 (75.9) 303 (66.9)
No 77 (30.4) 14 (24.1) 150 (33.1)
Oral anticoagulant Indirect oral anticoagulant 179 (70.8) 53 (91.4) 248 (54.7)
Warfarin 161 (63.6) 44 (83.0) 223 (49.2)
Acenocoumarol 18 (7.1) 9 (17.0) 25 (5.5)
Direct oral anticoagulant 74 (29.2) 5 (8.6) 205 (45.3)
Dabigatran 35 (13.8) 3 (5.2) 125 (27.6)
Rivaroxaban 21 (8.3) 1 (1.7) 42 (9.3)
Apixaban 16 (6.3) – 35 (7.7)
Edoxaban 2 (0.8) 1 (1.7) 3 (0.7)
Number of reported suspected drugs >1 24(9.5) 17 (29.3) 36 (7.9)
1 229 (90.5) 41 (70.7) 417 (92.1)
acenocoumarol, 14 to dabigatran, five to rivaroxaban, and five
to apixaban (Table 4). These bleeding events were mostly
distributed into the group “upper gastrointestinal bleeding”
for warfarin, acenocoumarol, and apixaban, and into the
group “lower gastrointestinal bleeding” for dabigatran and
rivaroxaban (Table 4). All cases had both narrative and
documental information required for the case evaluation.
Preventability of Cases of Bleeding
In total, 58 cases out of 253 (22.9%) were preventable.
Preventable cases were mostly reported by healthcare structures
located in the province of Avellino (N = 39; 67.2%), followed
by Napoli (N = 8; 13.8%), Caserta (N = 7; 12.1%), and
Benevento (N = 4; 6.9%). A full agreement was reached for
all cases by clinical pharmacologists involved in preventability
assessment. Considering the hemorrhagic nature of these
events, the underlying mechanism of ADRs was classified
as dose-related in all cases (Figure 1). Sixty-eight critical
criteria related to healthcare professionals’ practices were
detected in 58 preventable cases (Supplementary Table S2).
Specifically, we observed five different categorizations of the
criteria related to health professionals’ practice. In 75.9% of
preventable cases, pharmacological and/or non-pharmacological
treatments (as action taken) were required to treat the
ADRs, of which 23 cases also required drug withdrawal.
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TABLE 2 | Adverse drug reactions (ADRs) not related to bleeding categorized by
system organ class (SOC) and three most reported preferred terms in Individual
Case Safety Reports (ICSRs) reporting anticoagulants as suspected drugs.
SOC and ADRs Number of cases (%)
Gastrointestinal disorders 115 (28.8)
Epigastric abdominal pain 28 (7.0)
Dyspepsia 28 (7.0)
Diarrhea 9 (2.3)
Investigations 95 (23.8)
Abnormal coagulation profile 35 (8.8)
Increased INR 28 (7.0)
Fluctuating INR 16 (4.0)
Nervous system disorders 33 (8.3)
Headache 7 (1.7)
Cerebrovascular accident 3 (0.8)
Stroke 3 (0.8)
Blood and lymphatic system disorders 31 (7.8%)
Anemia 21 (5.3)
Thrombocytopenia 3 (0.8)
Pancytopenia 1 (0.3)
General disorders and administration site conditions 26 (6.5)
Asthenia 7 (1.7)
Therapeutic failure 4 (1.0)
Facial edema 2 (0.5)
Skin and subcutaneous tissue disorders 24 (6.0)
Itch 5 (1.2)
Sweating 3 (0.8)
Erythema 2 (0.5)
Renal and urinary disorders 13 (3.3)
Renal failure 6 (1.5)
Renal lesion 2 (0.5)
Decreased renal function 1 (0.3)
Respiratory, thoracic, and mediastinal disorders 12 (3.0)
Dyspnea 8 (2.0)
Cough 1 (0.3)
Respiratory distress 1 (0.3)
Vascular disorders 12 (3.0)
Thrombosis 2 (0.5)
Hypertension 2 (0.5)
Vasculitis 1 (0.3)
Cardiac disorders 9 (2.3)
Atrial fibrillation 4 (1.0)
Palpitation 1 (0.3)
Pericardial effusion 1 (0.3)
Ear and labyrinth disorders 6 (1.5)
Vertigo 4 (1.0)
Peripheral vertigo 2 (0.5)
Psychiatric disorders 6 (1.5)
Drowsiness 2 (0.5)
Hallucination 1 (0.3)
Agitation 1 (0.3)
Hepatobiliary disorders 5 (1.2)
Hypertransaminasemia 1 (0.3)
Cholangitis 1 (0.3)
Jaundice 1 (0.3)
(Continued)
TABLE 2 | Continued
SOC and ADRs Number of cases (%)
Injury, poisoning, and procedural complications 3 (0.8)
Overdose 2 (0.5)
Contusion 1 (0.3)
Musculoskeletal and connective tissue disorders 3 (0.8)
Joint effusion 1 (0.3)
Hydrarthrosis 1 (0.3)
Rhabdomyolysis 1 (0.3)
Infections and infestations 3 (0.8)
Rhinopharyngitis 1 (0.3)
Infections 1 (0.3)
Urinary infection 1 (0.3)
Eye disorders 1 (0.3)
Diplopia 1 (0.3)
Immune system disorders 1 (0.3)
Allergy 1 (0.3)
Metabolism and nutrition disorders 1 (0.3)
Inappetence 1 (0.3)
Total 399 (100.0)
INR: international normalized ratio.
Characteristics of preventable cases are reported in Table 1
and the clinical description of each case is reported in
Supplementary Table S2. The median times to event were
8 days [interquartile range (IQR): 5–31], and 1533 days
(IQR: 328–4805) for DOAC and indirect oral anticoagulants,
respectively (Figure 2).
Preventable Cases Related to the Use of Indirect
Oral Anticoagulants
In 53 out of 58 (91.4%) preventable cases, the reported
suspected drug was an indirect oral anticoagulant. Specifically,
44 (83.0%) cases reported as suspected drug warfarin and
9 (17.0%) cases reported as suspected drug acenocoumarol.
A total of 59 critical criteria related to healthcare professionals’
practices were identified. The most detected critical criteria
were labeled drug–drug interactions (50/59; 84.7%), followed
by the inappropriate prescription for patient’s underlying
medical condition (6/59; 10.2%), and the wrong indication
(3/59; 5.1%). A total of 94 drugs were involved in labeled drug–
drug interactions. The most reported drug–drug interactions
were with proton pump inhibitors (26/50; 52.0%), or statins
(15/50; 30.0%). Accordingly, the active ingredients most
involved in drug-drug interactions were pantoprazole (9/94;
9.6%), lansoprazole (9/94; 9.6%), allopurinol (7/94; 7.4%),
omeprazole (6/94; 6.4%), acetylsalicylic acid (5/94; 5.3%),
atorvastatin (5/94; 5.3%), amiodarone (5/94; 5.3%), and
simvastatin (4/94; 4.2%) (Supplementary Table S2). The most
reported inappropriate prescription for patient’s underlying
medical condition was the prescription of an indirect oral
anticoagulant in a patient with ulcer (4/6; 66.6%), erosive
gastroduodenitis (1/6; 16.7%), or history of cerebral hemorrhage
(1/6; 16.7%). The three preventable cases related to a wrong
indication were the use of an indirect oral anticoagulant for
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TABLE 3 | Adverse drug reactions related to bleeding categorized by system organ class (SOC) in Individual Case Safety Reports (ICSRs) reporting oral anticoagulants
as suspected drugs.
SOC Reported adverse events Cases with indirect oral
anticoagulants N (%)
Cases with direct oral
anticoagulants N (%)
Gastrointestinal disorders 56 (29.0) 37 (44.0)
Rectal bleeding 15 (7.8) 11 (13.1)
Bleeding gums 9 (4.7) 3 (3.6)
Melena 14 (7.3) 7 (8.3)
Hematemesis 7 (3.6) 1 (1.2)
Bleeding in the digestive tract 4 (2.1) 1 (1.2)
Erosive gastritis 2 (1.0) –
Abdominal hematoma 1 (0.5) –
Bleeding in the tongue 1 (0.5) –
Gastric bleeding 1 (0.5) 2 (2.4)
Gastric ulcer 1 (0.5) –
Gastrointestinal bleeding – 3 (3.6)
Intestinal bleeding – 4 (4.8)
Duodenal ulcer bleeding 1 (0.5) –
Bleeding of hemorroids – 1 (1.2)
Hemorrhagic intestinal diverticulitis – 1 (1.2)
Bleeding in the mouth – 1 (1.2)
Bleeding from polyps – 1 (1.2)
Esophageal ulcer – 1 (1.2)
Respiratory, thoracic, and mediastinal disorders 87 (45.1) 14 (16.7)
Epistaxis 78 (40.4) 10 (11.9)
Hemoptysis 6 (3.1) 2 (2.4)
Blood-tinged sputum 2 (1.0) –
Coughing up blood 1 (0.5) 1 (1.2)
Hemothorax – 1 (1.2)
Renal and urinary disorders 20 (10.4) 8 (9.5)
Hematuria 19 (9.8) 7 (8.3)
Hemorrhagic cystitis 1 (0.5) –
Chromaturia – 1 (1.2)
Vascular disorders 11 (5.7) 8 (9.5)
Hematoma 4 (2.1) 2 (2.4)
Hemorrhage 7 (3.6) 5 (6.0)
Hemorrhagic shock – 1 (1.2)
Skin and subcutaneous tissue disorders 4 (2.1) 3 (3.6)
Ecchymosis 3 (1.6) –
Bleeding of skin ulcer 1 (0.5) –
Petechia – 2 (2.4)
Lower extremity ulcer – 1 (1.2)
Nervous system disorders 11 (5.7) 5 (6.0)
Cerebral hemorrhage 9 (4.7) 4 (4.8)
Cerebrovascular accident 1 (0.5) –
Hemorrhagic stroke 1 (0.5) –
Intracerebral hemorrhage – 1 (1.2)
Musculoskeletal and connective tissue disorders 1 (0.5) 1 (1.2)
Muscle hematoma 1 (0.5) –
Hemarthrosis – 1 (1.2)
Eye disorders 1 (0.5) 1 (1.2)
Conjunctival hemorrhage 1 (0.5) 1 (1.2)
(Continued)
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TABLE 3 | Continued
SOC Reported adverse events Cases with indirect oral
anticoagulants N (%)
Cases with direct oral
anticoagulants N (%)
Injury, poisoning, and procedural complications 2 (1.0) 4 (4.8)
Subdural hemorrhage 1 (0.5) –
Subdural hematoma 1 (0.5) 3 (3.6)
Epidural hematoma – 1 (1.2)
Reproductive system and breast disorders – 3 (3.6)
Menorrhagia – 1 (1.2)
Vaginal bleeding – 1 (1.2)
Intermenstrual bleeding – 1 (1.2)
TABLE 4 | Distribution of upper and lower gastrointestinal bleedings for each
oral anticoagulant.
Oral anticoagulant Upper
gastrointestinal
bleeding N (%)
Lower
gastrointestinal
bleeding N (%)
Warfarin 22 (62.9) 13 (37.1)
Acenocoumarol 4 (80) 1 (20)
Dabigatran 5 (35.7) 9 (64.3)
Rivaroxaban 2 (40) 3 (60)
Apixaban 4 (80) 1 (20)
peripheral obliterating arteriopathy, acute heart failure, or
hypertension. Details for each preventable case are provided in
Supplementary Table S2.
Preventable Cases Related to the Use of Direct Oral
Anticoagulants
In five out of 58 (8.6%) preventable cases, the reported
suspected drug was a DOAC. Specifically, three (60.0%)
cases reported as suspected drug dabigatran, one case
rivaroxaban, and one case edoxaban. A total of nine
critical criteria were identified. All criteria were related
to healthcare professionals’ practices. The most detected
critical criteria were labeled drug–drug interactions (3/9;
33.3%), followed by the incorrect dose (3/9; 33.3%), and the
inappropriate prescription according to the characteristics
of the patient (3/9; 33.3%). The three cases of labeled drug–
drug interaction reported as suspected drugs rivaroxaban,
dabigatran, and edoxaban. In one case, the labeled drug–
drug interaction was the concomitant prescription of
rivaroxaban and methimazole in accordance with the
SmPC of methimazole. Another case was related to the
concominant administration of dabigatran and amiodarone.
The last case is the concomitant intake of edoxaban and
acetylsalicylic acid in an elderly patient. The critical criteria
incorrect dose and inappropriate prescription according
to the characteristics of the patient were reported in the
same three cases and were all related to the suspected
drug dabigatran. In these cases, the patient was treated
with 220 mg/day of dabigatran, but according to the
SmPC, the recommended dose in elders (>75 years) is
150 mg/day. Details for each preventable case are provided in
Supplementary Table S2.
Comparison of the Reporting Probability
of Lower/Upper Gastrointestinal
Bleeding Among Oral Anticoagulants
Dabigatran was associated with an increased reporting
probability of lower gastrointestinal bleedings rather than
upper gastrointestinal bleedings if compared to warfarin
(ROR 0.33, 95%CI 0.09–1.19; reference group: dabigatran),
acenocoumarol (ROR 0.14, 95%CI 0.01–1.61; reference group:
dabigatran), rivaroxaban (ROR 0.83, 95%CI 0.10–6.78; reference
group: dabigatran), and apixaban (ROR 0.14, 95%CI 0.01–1.61;
reference group: dabigatran). Abovementioned computations
were not statistically significant; however, we had no statistical
power to detect statistically significant associations as described
in Table 5.
DISCUSSION
This is the first study conducted in our national territory
to assess the preventability of oral anticoagulant-induced
bleedings among ICSRs sent through the Campania region
(Italy) spontaneous reporting system from 1 July 2012 to
31 December 2017.
Considering the few information available on the
preventability of anticoagulant-induced bleedings, especially in
Italy, our results may be of great novelty because we were able to
provide “real-world evidence” on the quota of preventable ICSRs
of bleeding in our Regional territory. Moreover, we provide
detailed information on the most reported risk factors for oral
anticoagulant-induced bleedings.
In our ICSRs, the mean age was 72.5 years (SD: 11.2 years)
in accordance with data showing that in elders anticoagulants
are one of main causes responsible for 60% of ADRs leading
to hospitalization and 70% of ADRs occurring in hospital
(Routledge et al., 2004). In addition, anticoagulants are more
likely than other drugs to cause ADRs that result or prolong
hospitalization (Davidsen et al., 1988; Bordet et al., 2001),
accordingly most of our cases classified as serious reported the
criteria “serious – hospitalization.”
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FIGURE 1 | Characteristics of bleeding cases involving oral anticoagulants recognized in Campania spontaneous reporting system from July 2012 to December
2017.
FIGURE 2 | Time to event of preventable cases. ICSRs were screened among those reported in Campania spontaneous reporting system from July 2012 to
December 2017.
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TABLE 5 | Reporting odds ratio of lower/upper gastrointestinal bleeding with oral anticoagulant with dabigatran as reference drug.
Oral anticoagulant Control group Reporting odds ratio (95% confidence interval) P-value Power (1 − beta error probability)
Warfarin Dabigatran 0.33 (0.09–1.19) 0.08 0.4
Acenocoumarol Dabigatran 0.14 (0.01–1.61) 0.08 0.38
Rivaroxaban Dabigatran 0.83 (0.10–6.78) 0.86 0.05
Apixaban Dabigatran 0.14 (0.01–1.61) 0.09 0.38
Despite in our Region, according to the last national
report on drug usage, DOACs are most frequently used than
indirect oral anticoagulants (7.2 DDD/1000/inhabitants/day vs.
2.2 DDD/1000/inhabitants/day) (AIFA, 2017), we observed a
total of 248 (54.7%) ICSRs that reported an indirect oral
anticoagulant as suspected drug. This may be related to the
narrow therapeutic window of VKAs compared with DOACs
(Fuster et al., 2006).
Overall, from our findings it emerged that abnormalities
in the INR, and gastrointestinal abdominal pain were
among non-bleeding cases most frequently associated
with oral anticoagulants, suggesting that these are the
main concerns today by both patients and doctors
during anticoagulant therapy. Accordingly, in the
literature, the most frequent anticoagulant-associated
ADRs are abnormal coagulation test, bleedings, and
thrombocytopenia (Piazza et al., 2011). In particular, the
occurrence of an excessive anticoagulant effect, such as
an increase of INR or of activated partial thromboplastin
time (aPTT), has been estimated approximately of 72%
(Piazza et al., 2011).
In the analysis of bleedings cases (N = 253), the most
reported suspected drug was an indirect oral anticoagulant
(70.8%). Moreover, we observed that most bleeding events
induced by indirect oral anticoagulant belonged to the
SOC “respiratory, thoracic, and mediastinal disorders”
(45.1%), while for DOACs most adverse events belonged
to the SOC “gastrointestinal disorders” (44%). This is in
accordance with the higher risk found in scientific literature
for the association DOACs and gastrointestinal bleedings
(Ruff et al., 2014; Monaco et al., 2017). In the evaluation
of upper and lower gastrointestinal bleedings, we were
able to classify just 64 ADRs, of which a high number was
reported with warfarin and dabigatran. Hemorrhagic events
reported with warfarin were more frequently classified as
upper gastrointestinal bleedings, while those reported with
dabigatran were mostly classified as lower gastrointestinal
bleedings. This is in accordance with data of a post hoc
analysis of the Randomized Evaluation of Long-Term
Anticoagulation Therapy (RE-LY) trial that has shown a
rate of upper gastrointestinal bleedings similar between
dabigatran and warfarin, whereas for lower gastrointestinal
bleeding, the rate was higher with dabigatran than warfarin
(Kolb et al., 2018). A hypothesis that could explain this
finding considers the pharmacokinetic profile of dabigatran
etexilate, which is absorbed principally in the stomach
and proximal small bowel as an inactive prodrug and then
converted to the active form by serum and hepatic esterases.
However, the bioavailability of dabigatran is low (3–7%) with
an unabsorbed quota being converted to active dabigatran
in the distal bowel and then excreted in the feces. This
active quota in the distal bowel may be responsible for the
onset of lower gastrointestinal bleeding, with a rate even
higher than warfarin, which is not activated in the bowel
(Feagins and Weideman, 2018).
Different factors are able to influence the risk of
gastrointestinal bleeding in patients treated with oral
anticoagulants, including the advancing age, concomitant
use of acetylsalicylic acid, history of gastrointestinal
bleedings, prior/current smokers, atrial fibrillation, and
other comorbidities (e.g., renal failure, anemia, diabetes
mellitus) (Di Minno et al., 2015). Accordingly, we
found that the most reported therapeutic indication
for oral anticoagulants was atrial fibrillation and
that among concomitant drugs there was the use of
acetylsalicylic acid.
For bleedings cases belonging to the SOC “nervous
system disorders,” according to literature, we found a
lower number of cases related to a DOAC than a VKA
(Eikelboom and Merli, 2016).
By applying the P-method, 58 (22.9%) cases of bleedings
were preventable, with a total of 68 critical criteria identified.
Considering the characteristics of patients in preventable
cases, it should be noted that the advanced age was the
most reported risk factor for bleedings. In addition, other
frequent reported bleeding risk factors were the concomitant
clinical conditions like hypertension, diabetes, hepatic or
renal damage, and cerebrovascular diseases. Other reported
risk factors, although rarely reported, were the prolonged
use of warfarin (more than 30 years), the presence of
malignancy (multiple myeloma), and hypochromic anemia
(AIFA, 2010; Di Minno et al., 2015). All critical criteria
were related to healthcare professionals’ practices, and the
most reported risk factor was the inappropriate prescription
of a drug able to induce drug–drug interactions with oral
anticoagulants. In this regard, the potential harm of the so-called
“polypharmacy” has been known for some time (Hudson,
1968) being considered as a major medical problem in some
countries, and a challenge for the World Health Organization
in organizing action programs on multiple therapy (Hogerzeil,
1995). For oral anticoagulants, the potential harm caused by
pharmacodynamics and pharmacokinetics interactions with
drugs, foods, herbs, and over-the-counter medications was
already described in an Italian critical review (Di Minno
et al., 2017). Unfortunately, we were able to focus only on
drug–drug interaction based on our data source and the
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preventability tool used. In our results, the most reported
drugs involved in drug–drug interactions with an indirect
oral anticoagulant were proton pump inhibitors, statins,
allopurinol, acetylsalicylic acid, and amiodarone. Accordingly,
the evidence suggests a role of the aforementioned drugs
as potential risk factors for the development of clinically
relevant drug–drug interaction leading to VKA-induced
ADRs (Nutescu et al., 2011; Forbes and Polasek, 2017). In
accordance with the scientific literature, drugs more involved
in drug–drug interaction with DOACs were amiodarone,
methimazole, and acetylsalicylic acid (Rafaniello et al., 2016;
Forbes and Polasek, 2017; Gelosa et al., 2018). While
amiodarone is involved in pharmacokinetic drug–drug
interaction as a moderate inhibitor of CYP3A4 and P-gp
(Forbes and Polasek, 2017), methimazole may induce a
pharmacodynamics interaction through its antivitamin K
property (AIFA, 2005). The double effect of antiplatelet
and anticoagulant therapy on the bleeding risk is well
known, and sometimes well accepted considering the
antithrombotic effect achieved by the combined treatment
(Dale et al., 1980). In fact, in our preventable case, the co-
treatment with apixaban and acetylsalicylic acid has only
caused a minor bleeding (epistaxis) in an elderly patient.
Moreover, six preventable cases of bleeding with indirect oral
anticoagulants were related to the inappropriate prescription
of warfarin in patients with hemorrhagic tendencies like
an ulcer, erosive gastroduodenitis, or history of cerebral
hemorrhage, which are all recognized as part of risk
prediction tools for anticoagulant-associated hemorrhages
(Shoeb and Fang, 2013).
Interesting, more than half of preventable cases required
a pharmacological and/or non-pharmacological treatment
to resolve the ADR, presuming a high potential clinical
and economic burden on the health care system (Sultana
et al., 2013). In this perspective, it seems very important
for Competent Authorities to promote the precocious
detection of ADRs, and initiatives to quantify their
preventable quota in order to reduce where possible the
healthcare costs.
We found a different median time to event for direct and
indirect oral anticoagulants that was higher for VKAs. One
possible explanation for this finding may be the different
monitoring of the therapy in patients treated with indirect
oral anticoagulants, which are more strictly monitored
in the first months of therapy than thereafter. On the
contrary, patients in therapy with DOAC are in a fixed-
dose regimen since the early start of treatment without
any need of routine coagulation monitoring or therapeutic
drug monitoring. This may predispose to some dosing error
especially in elders. In fact, three of our preventable cases
were related to the administration of a dabigatran dose
exceeding the maximum recommended dosage in the SmPC for
elderly patients.
This study has been promoted by the Campania
Pharmacovigilance Regional Centre as part of initiatives
to ensure drug safety during the last years (Sessa et al.,
2015, 2016a,d; Auricchio et al., 2017; Mascolo et al., 2017;
Scavone et al., 2017), and based on our results, other
initiatives will be started to establish a proper diagnostic
therapeutic plan for the management of anticoagulant
therapy and their ADRs, especially in those provinces
with the high amount of preventable cases. Moreover,
the promotion of appropriate use of these drugs could
implicate a massive benefit in terms of public health
for our Regional territory, considering also the high
morbidity and mortality associated with cardiovascular
diseases. Therefore, the appropriate use of drugs like oral
anticoagulants may highly affect and reduce cardiovascular
risk, becoming highly beneficial for both patients and the
National Health Service.
Strengths and Limitations
Our study has both strengths and limitations. An
important strength of this study was the use of a validated
tool to quantify preventable cases of ADRs potentially
related to oral anticoagulants. However, an important
limitation is the lack of generalizability due to the fact
that the description of ICSRs characteristics associated
with oral anticoagulant takes into account only a small
population of an Italian region. Moreover, this study has
all the limitations of the spontaneous reporting system,
such as underreporting, differential reporting, irregular
information quality, and lack of denominator data such
as the user population and drug-exposure patterns. For
this reason, the population in our study included only
oral anticoagulant-induced ADRs patients rather than
oral anticoagulant-exposed patients. Furthermore, another
important limitation is the lack of information about
possible drug–food or drug–herb interactions that cannot
be detected for sure through the spontaneous reporting.
In fact, this information is not an essential requirement
for the spontaneous reporting of suspected ADRs but
could represent an important risk factor for the detection
of preventable ADRs whether it is added. Therefore,
preventability tools that focus also on this aspect should
be investigated.
CONCLUSION
This is the first study that described preventable cases of
oral anticoagulants-related bleedings, of which all cases
were related to healthcare professionals’ practices. The most
detected critical criterion identified through the application
of a validated tool for preventability assessment was the
drug-drug interaction. Moreover, 48% of the preventable
cases were classified as serious and 69% was associated
with a positive outcome. We believe that an improvement
of pharmacovigilance activities in our regional territory
is needed to put into clinical practice the knowledge of
the risk factors for oral anticoagulant-induced bleedings
and to reduce the burden of medication errors and
inappropriate prescription. Based on our results, several
initiatives will be started in the Campania region to
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share the acquired experiences in routine clinical practice
in order to promote the more appropriate use of oral
anticoagulant therapy.
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